Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX18 Avapritinib
D11279 Avapritinib (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
PDGFR Alpha Inhibitors
Avapritinib
D11279 Avapritinib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D11279 Avapritinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRA* [HSA_VAR:5156v2]
D11279 Avapritinib (USAN/INN) <US>
KIT* (CD117) [HSA_VAR:3815v1]
D11279 Avapritinib (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11279
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11279
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11279
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11279